{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:48:47Z","timestamp":1781801327126,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Zenyaku Kogyo"},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12185-016-2097-9","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T08:50:35Z","timestamp":1475743835000},"page":"700-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden"],"prefix":"10.1007","volume":"104","author":[{"given":"Tadahiko","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Nawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"2097_CR1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435\u201345.","journal-title":"Blood"},{"key":"2097_CR2","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295\u2013301.","journal-title":"Blood"},{"key":"2097_CR3","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853\u20138.","journal-title":"J Clin Oncol"},{"key":"2097_CR4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27:1607\u201314.","journal-title":"J Clin Oncol"},{"key":"2097_CR5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088\u201395.","journal-title":"J Clin Oncol"},{"key":"2097_CR6","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00a0\u00d7\u00a04 schedule. Blood. 2004;103:4416\u201323.","journal-title":"Blood"},{"key":"2097_CR7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103:1799\u2013806.","journal-title":"J Natl Cancer Inst"},{"key":"2097_CR8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"2097_CR9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","volume":"122","author":"JF Seymour","year":"2013","unstructured":"Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Updated 6\u00a0year follow-up of the PRIMA Study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood. 2013;122:509 (abstract).","journal-title":"Blood"},{"key":"2097_CR10","volume-title":"World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001."},{"key":"2097_CR11","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","volume":"17","author":"D Decaudin","year":"1999","unstructured":"Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, et al. Low-grade stage III\u2013IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients\u2014a study of the Groupe d\u2019 Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1999;17:2499\u2013505.","journal-title":"J Clin Oncol"},{"key":"2097_CR12","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-C\u00e9ligny","year":"1998","unstructured":"Solal-C\u00e9ligny P, Lepage E, Brousse N, Tendler CL, Brice P, Ha\u00efoun C, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332\u20138.","journal-title":"J Clin Oncol"},{"key":"2097_CR13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"2097_CR14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","volume":"97","author":"M Ogura","year":"2006","unstructured":"Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci. 2006;97:305\u201312.","journal-title":"Cancer Sci"},{"key":"2097_CR15","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1111\/j.1349-7006.2010.01703.x","volume":"101","author":"K Tobinai","year":"2010","unstructured":"Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, et al. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Cancer Sci. 2010;101:2579\u201385.","journal-title":"Cancer Sci"},{"key":"2097_CR16","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, B\u00f6ck HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular. Blood. 2006;108:4003\u20138.","journal-title":"Blood"},{"key":"2097_CR17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143\u201351.","journal-title":"Biometrics"},{"key":"2097_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"Kaplan El","year":"1958","unstructured":"El Kaplan, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"2097_CR19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Coligny","year":"2004","unstructured":"Solal-Coligny P, Roy P, Colombat P. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"2097_CR20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","volume":"137","author":"D Behl","year":"2007","unstructured":"Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409\u201315.","journal-title":"Br J Haematol"},{"key":"2097_CR21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12185-014-1576-0","volume":"99","author":"S Kumagai","year":"2014","unstructured":"Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014;99:737\u201342.","journal-title":"Int J Hematol"},{"key":"2097_CR22","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990\u20138.","journal-title":"J Clin Oncol"},{"key":"2097_CR23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268\u201376.","journal-title":"J Clin Oncol"},{"key":"2097_CR24","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-L\u00f3pez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711\u20136.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12185-016-2155-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2097-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T12:47:07Z","timestamp":1601124427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2097-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2097-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-016-2155-3","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}